Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
NCT00034281
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasm
Pancreatic Neoplasm
Lung Neoplasm
Ovarian Neoplasm
Renal Neoplasm
Interventions
DRUG:
TAK-165
Sponsor
Takeda